Apnimed, Inc. Common Stock

Apnimed has been added to the NASDAQ Composite Index, increasing its visibility among index-following investors. The inclusion can lead to higher trading liquidity as more funds and investors track or reference the NASDAQ Composite. The move is often viewed as recognition of a company's progress and operational milestones within the public markets. Apnimed is a US pharmaceutical company with a market cap of $1.1b that focuses on developing oral therapies targeting the neurobiology of sleep-related breathing diseases in global markets. The company still faces underlying financial questions, including weak coverage of debt by operating cash flow and negative shareholders equity.

Apnimed has closed its upsized initial public offering, raising gross proceeds of $220.8 million before deducting underwriting discounts and offering expenses. The late-stage clinical pharmaceutical company sold an aggregate of 13,800,000 shares of common stock at $16.00 per share, which included the full exercise of the underwriters' overallotment option to purchase an additional 1,800,000 shares. The shares began trading on the Nasdaq Global Select Market on July 31, 2026, under the ticker symbol APMD. BofA Securities, Evercore ISI, Cantor, and LifeSci Capital acted as joint book-running managers for the offering.